| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H31NO7S |
| Molecular Weight | 465.56 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
InChI
InChIKey=UQZVCDCIMBLVNR-TWYODKAFSA-N
InChI=1S/C23H31NO7S/c1-32(29,30)24-23(28)12-8-3-2-7-11-19-20(22(27)15-21(19)26)14-13-17(25)16-31-18-9-5-4-6-10-18/h2,4-7,9-10,13-14,17,19-20,22,25,27H,3,8,11-12,15-16H2,1H3,(H,24,28)/b7-2-,14-13+/t17-,19-,20-,22-/m1/s1
| Molecular Formula | C23H31NO7S |
| Molecular Weight | 465.56 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
Sulprostone, a P1/EP3 prostanoid receptor agonist, participated in trials for ending pregnancy after fetal death between 14 and 42 weeks gestation. This drug was also studied for treating severe atonic postpartum hemorrhage after vaginal delivery and for management of retained placenta. Moreover, recent investigations have revealed, that sulprostone could be a valuable drug candidate in the therapy of many pathophysiological states, including ulcerative colitis, glaucoma, and bone healing.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 1.6 nM [EC50] |
PubMed
Showing 1 to 5 of 6 entries
